Enveda Biosciences is revolutionizing the biotechnology industry with its groundbreaking approach to drug discovery. With $51 million raised in their Series B funding from investors Kinnevik, True Ventures, FPV Ventures, Dimension Inx, and Wireframe Ventures, this Boulder-based startup, founded by Viswa Colluru, is transforming nature into new medicines by unlocking our planet's chemistry. Enveda's platform is designed to probe the 95% of the natural world that is still a chemical mystery and rapidly search for new leads to develop approved small molecule medicines. Enveda's cutting-edge methods are creating the world's most diverse biologically annotated dataset of small molecules, allowing them to query chemical structure, biological activity, and organ distribution to rapidly search for new leads.

Using their breakthroughs in machine learning, metabolomics, and robotics, Enveda is breaking free of the bottlenecks of isolating and studying one molecule at a time. With their proprietary high-throughput screening methods and generative deep learning models, Enveda can predict chemical properties and structure directly with high accuracy from MS2 spectra and find hundreds of active compounds at once. Enveda is committed to delivering hope to every patient, ensuring that soon, patients and their families will always have hope.